Personalized anticancer therapy

Size: px
Start display at page:

Download "Personalized anticancer therapy"

Transcription

1 July 2015 Personalized anticancer therapy Israel R&D : Caesarea Business Park, P.O 4463 Caesarea Israel. U.S Office: #3 Bethesda Metro Center Suite 700 Bethesda, MD.

2 Company overview Cannabics Pharmaceuticals Inc. is engaged in the development and commercialization of personalized anticancer Cannabis based medicine. Cannabics focuses on the personalization of natural anticancer therapy. Utilizing throughput technology, we screen antitumor effects on biopsies treated with natural compounds. Since cannabis is known for its antitumor properties and has a great variance of active compounds, this in-vitro diagnostics process points out specific cannabis extracts with the potential of serving not only as a palliative treatment but also as an anticancer therapy. This technology enables the entourage of active ingredients found in diverse strains of cannabis to be harnessed in the fight against the diversity and sustainability of tumors. Personalized anticancer medicine There is a large cumulative and rapidly growing body of scientific data, which clearly indicates that cannabinoids specifically inhibit cancer cell growth and promote cancer cell death through apoptosis. We have developed an automated high-throughput method for the screening of different types of cancer cells or biopsies treated with a multitude of cannabis extracts. These natural extracts could also be tested in conjunction with approved synthetic drugs for patients that undergo chemotherapy for the most personally tailored therapy. This multilayer method is producing a large-scale database that will capture the knowledge gained on to the unique effects of different combinations of cannabinoid compounds on diverse malignancies. Coextensive with the development of the automated high-throughput 2

3 system, we are also developing proprietary and novel compounds targeted on diverse types of tumors. The advantages of Natural personalized Therapy Bio versatility- most drugs in the market are based on one active molecule, which has a well-established effect on the biology of the patient but usually, has harsh side effects for the same reason. It is more likely to assume that a large variety of molecules would treat a highly varied disease as cancer with more efficacy. Personalized Medicine -PM is treating the individual rather than groups of people. There are over 200 different known cancers and the genetic divergence among humans makes it nearly impossible to find one remedy for a group of people. PM is aiming to create a therapy for the biology of an individual by using personal biological data. Natural product- all natural compounds derived from the cannabis plant are well known for their non-toxic nature while standard chemotherapy is considered highly toxic with harsh side effects and in some cases cancerous itself. Cannabics SR As means of cannabis administration, Cannabics has developed a patent pending extended release formulation, distributed in Colorado as WannaCaps XR and studied as a palliative treatment for cancer patients in a renowned medical center in Israel. 3

4 A patent pending extended release cannabis capsule The Company s marketed product is Cannabics SR, an extended release oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR 10mg delivers a steady level of beneficial effects for 6-8 hours. The once to twice per-day oral dosing regimen offered by Cannabics SR allows patients a more consistent beneficial effect without the dizziness and dissociation commonly found with immediate release administration methods or the inconvenience of frequent re-dosing. It also avoids the medical complications associated with smoking cannabis and the uneven dosage frequently encountered in other edibles. Cannabics SR Clinical Research and Development On July 2014, the Company filed a non-provisional patent application with the U.S. Patent & Trademark Office and an international patent application with the Patent Cooperation Treaty division of the Israeli Patent Office, each covering the proprietary technology underlying Cannabics SR. A clinical study in underway in the Oncology Department of the Rambam Medical Center will examine the effectiveness of Cannabics SR in reducing nausea and improving the appetite of oncology patients, as 4

5 well as general improvement in quality of life and reduction of depression. We expect the first results to be available in September You can find this study under Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients or from the NIH Clinical Trials website: https://clinicaltrials.gov/ct2/show/study/nct contacts You can also see a more in-depth review at the (US) National Cancer Institute s website: althprofessional&protocolsearchid= We believe that clinical proof of safety and efficacy is of very high importance for the medical community and particularly to prescribing physicians. We anticipate that successful completion of our upcoming clinical studies with the Cannabics SR capsules will further legitimize the use of the capsules in the eyes of the medical community and will facilitate market penetration of Cannabics SR through coverage in publications by key opinion leaders in palliative oncology. Cannabis SR in the U.S. market In December 2014, the Company and Mountain High Products LLC, a Colorado corporation based in Boulder, Colorado, executed a Letter of Engagement contemplating the grant of a license to Mountain High for the exclusive production and distribution of Cannabics SR technology in the USA under the label Wanacaps XR. 5

6 Wanacaps XR Three versions of Wanacaps XR are available in Colorado: High THC Capsules 10 mg of THC, 1 mg of CBD. THC/CBD Balanced Capsules --10 mg of THC and 10 mg of CBD. High CBD Capsules 10 mg of CBD, 1 mg of THC. In The news: 6

7 The Board Dr. Eyal Ballan - Co-founder and CTO Dr. Eyal Ballan is a co-founder of Cannabics Pharmaceuticals and serves as CTO. Dr. Ballan holds a Ph.D. in neurophysiology, EEG Brain wave analysis and attention. After his Ph.D. he was an entrepreneur in the field of biofeedback and developed a resonating neuro-feedback system. Dr. Ballan holds a M.Sc. in cancer research and was part of the research team who developed Salirasib (Treatment for Non-Small Cell Lung Cancer). His expertise is in molecular biology, cell cultures and genomics and neurophysiology. Mr. Itamar Borochov - Co-founder and CEO Mr. Borochov is an environmentalist with vast experience as an entrepreneur in the fields of organic agriculture and medical cannabis. For more than 15 years prior to his involvement with medical cannabis, Mr. Borochov was a real estate entrepreneur. Mr. Shay Avraham Sarid - Co-founder Mr. Sarid is a co-founder of Cannabics Inc. and he is also the founder of Seach, one of the oldest and largest medical Cannabis farms in Israel. Seach is an official supplier of medical grade Cannabis to the Israeli Ministry of Health and specifically licensed to grow and distribute medical cannabis to authorized patients. Shay is the recent Chairman of the Israeli Medical Cannabis Growers Council. 7

8 Mr. Dov Weinberg Chief Financial Officer Mr. Weinberg has over 30 years of broad experience in corporate finance including more than 13 years in the Bio-tech, life science and medical device industries. He has been in executive positions for several US public companies including their world-wide subsidiaries. Mr. Weinberg is a Certified Public Accountant since 1979 and holds an MBA from Bar Ilan University (1984) and a B.A. in Economics and Accounting from Tel Aviv University (1977). Mr. David E. Price, Esq. Mr. David E. Price is our Secretary and corporate attorney, a native Washingtonian & has lived both in America and Israel & is fluent in several languages. David brings a dynamic and varied background, having worked in the Diplomatic Corps in the Israeli Foreign Office as well as a Congressional Aide in the US Congress, and General Counsel to consultants at the World Bank as well as the IDB, EX-IM and IMF in Washington, DC. He left a large international firm to create his own niche solo practice in mergers & acquisitions and brings years of knowledge both general and specific in the international business and corporate. Board of Advisors Dr. Sigalit Ariely-Portnoy Senior advisor in the field of regulation, validation and quality, Dr. Sigalit Ariely-Portnoy has over 17 years experience in the pharmaceutical industry. During this time, she has managed pharmaceutical and chemical plants at Taro pharmaceutical industries as Operation Group Vice president and in Teva Pharmaceutical industries. she managed Teva's largest plant worldwide. 8

9 During her career, she led more than 50 inspections by the US FDA, EMEA, Israeli MOH, and others. Dr. Ariely-Portnoy received her B.Sc., M.Sc., and D.Sc. from the Technion Institute of Technology in Haifa, Israel, in the fields of Chemical Engineering and Biomedical Engineering. Mr. Isaac Abravanel Senior advisor in the field of operational and strategic planning, Mr. Isaac Abravanel joined Teva Pharmaceutical Industries Ltd as its Corporate Vice President of Human Resources in During 2009, Mr. Abravanel was appointed as Teva s Chief Integration Officer, and as such led the postmerger integration processes of Teva s large acquisitions in recent years. In 2013 Mr. Abravanel was appointed as Group Executive Vice President of Teva Corporate in Israel and Global Community Alliances of Teva Pharmaceutical Industries Ltd. Mr. Abravanel holds a B.A and an M.A. in Political Science from Haifa University and is a Graduate of the National Security College. 9

Research: Medical Cannabis

Research: Medical Cannabis Research: Medical Cannabis Background The hemp plant Cannabis sativa (cannabis) is commonly known as marijuana and can be used as a therapy to alleviate symptoms such as pain and fatigue caused by chronic

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

MEDICINAL CANNABIS IN ISRAEL, 2015

MEDICINAL CANNABIS IN ISRAEL, 2015 MEDICINAL CANNABIS IN ISRAEL, 2015 Ilya Reznik M.D. Chief Physician, MaReNa Consulting Center, Israel Coordinator, Israel Forum/Association for Medical Cannabis Research and Treatment Board of Directors,

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

Clinical and Therapeutic Cannabis Information. Written by Cannabis Training University (CTU) All rights reserved

Clinical and Therapeutic Cannabis Information. Written by Cannabis Training University (CTU) All rights reserved Clinical and Therapeutic Cannabis Information Written by Cannabis Training University (CTU) All rights reserved Contents Introduction... 3 Chronic Pain... 6 Neuropathic Pain... 8 Movement Disorders...

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

ALLOS THERAPEUTICS, INC. 2000 ANNUAL REPORT. Building an. Oncology Franchise

ALLOS THERAPEUTICS, INC. 2000 ANNUAL REPORT. Building an. Oncology Franchise ALLOS THERAPEUTICS, INC. 2000 ANNUAL REPORT Building an Oncology Franchise Allos is a product company that develops and commercializes small molecule oncology and cardiovascular drugs. Our lead product

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

EXIQON TO ACQUIRE ONCOTECH INC AND ENTER THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS IN 2008

EXIQON TO ACQUIRE ONCOTECH INC AND ENTER THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS IN 2008 Announcement no. 22/2007 To OMX The Nordic Exchange, Copenhagen, and the press Vedbæk, November 27, 2007 EXIQON TO ACQUIRE ONCOTECH INC AND ENTER THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS IN 2008 Summary:

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September

More information

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 NHLBI SAN DIEGO INNOVATION CONFERENCE JUNE 11, 2013 Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 Agenda Speaker Bios 10:30-11:00 a.m. Registration 11:00-11:15 a.m. Welcome Remarks

More information

IN THE SENATE OF THE UNITED STATES

IN THE SENATE OF THE UNITED STATES II D CONGRESS 1ST SESSION S. 1 To amend title XVIII of the Social Security Act to provide for uniform coverage of anticancer drugs under the medicare program, and for other purposes. IN THE SENATE OF THE

More information

PROQUEST DISSERTATIONS AND THESES PROFESSIONAL

PROQUEST DISSERTATIONS AND THESES PROFESSIONAL NEW ON PROQUEST DIALOG PROQUEST.COM PROQUEST S AND THESES PROFESSIONAL START HERE Scientific research drives innovation for your industry and your organization, but do you have the complete perspective?

More information

National Framework for Excellence in

National Framework for Excellence in National Framework for Excellence in Lung Cancer Screening and Continuum of Care declaration of purpose Rights and Expectations THE RIGHTS OF THE PEOPLE Lung cancer kills more Americans than the next four

More information

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee

Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:

More information

Annette E. Fleckenstein, M.S., Ph.D.

Annette E. Fleckenstein, M.S., Ph.D. Annette E. Fleckenstein, M.S., Ph.D. Professor of Dentistry Deputy Director, Utah Addiction Center University of Utah http://healthsciences.utah.edu/utahaddictioncenter/ fleckenstein@hsc.utah.edu Marijuana

More information

What is Glioblastoma? How is GBM classified according to the WHO Grading System? What risk factors pertain to GBM?

What is Glioblastoma? How is GBM classified according to the WHO Grading System? What risk factors pertain to GBM? GBM (English) What is Glioblastoma? Glioblastoma or glioblastoma multiforme is one of the most common brain tumors accounting for approximately 12 to 15 percent of all brain tumors. The name of the tumor

More information

Profile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization Washington-Baltimore Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Washington-Baltimore The Washington,

More information

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

More information

The Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor

The Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor The Biotech Business Life Cycle and The Lawyer s Role as Counselor and Advisor ASU February 15, 2010 1 BIOTECH BUSINESS CYCLE AN INTERDISCIPLINARY APPROACH TO LEGAL REPRESENTATION Intellectual Property

More information

MediSapiens Ltd. Bio-IT solutions for improving cancer patient care. Because data is not knowledge. 19th of March 2015

MediSapiens Ltd. Bio-IT solutions for improving cancer patient care. Because data is not knowledge. 19th of March 2015 19th of March 2015 MediSapiens Ltd Because data is not knowledge Bio-IT solutions for improving cancer patient care Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd Copyright 2015 MediSapiens Ltd. All

More information

Houston Cancer Institute

Houston Cancer Institute Houston Cancer Institute A personal path to healing Memorial-West Houston Katy Northwest Houston Southeast Houston Sugar Land Convenience for Patients State of the Art Therapies and Diagnosis Real Support

More information

Biosimilars 20/20. The Future is at Hand

Biosimilars 20/20. The Future is at Hand Welcome to Biosimilars 20/20, presented by the Specialty Pharma Education Center (SPEC) in partnership with the Specialty Pharma Journal (SPJ). Please note that this is a preliminary agenda that is subject

More information

CTC Technology Readiness Levels

CTC Technology Readiness Levels CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.

More information

For personal use only

For personal use only 6 July 2015 KEY ADVANCEMENT TOWARDS COMMENCEMENT OF PHASE 1 CLINICAL STUDY OF ORAL FORMULATIONS Highlights PhytoTech Medical has submitted key documents to the Institutional Review Board (IRB or Helsinki

More information

SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY

TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY Key Takeaways from the June 18, 2013 Regional Symposium Nashville, Tennessee THE SYMPOSIUM Trends Shaping the Future

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

How Can Institutions Foster OMICS Research While Protecting Patients?

How Can Institutions Foster OMICS Research While Protecting Patients? IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice

More information

Masters Learning mode (Форма обучения)

Masters Learning mode (Форма обучения) Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)

More information

BNC105 PHASE II RENAL CANCER TRIAL RESULTS

BNC105 PHASE II RENAL CANCER TRIAL RESULTS ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient

More information

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION

More information

PATENTS. Pharmaceutical Product Patenting Strategies

PATENTS. Pharmaceutical Product Patenting Strategies PATENTS Pharmaceutical Product Patenting Strategies 1. What is a product patent? A product patent is a patent giving protection to a product as such, e.g. as an apparatus, a device or a chemical compound.

More information

BDO-I2I India Business Consulting. Company Profile

BDO-I2I India Business Consulting. Company Profile BDO-I2I India Business Consulting Company Profile Page 2 BDO-I2I Overview BDO-I2I is Israel s leading India focused business consulting firm Joint venture between BDO Consulting Group and I2I Ventures

More information

PARTNER SEARCH FORM. MedAdvizor.org. Type of Company x HT R&D Research Institute University Other. Year Established 2013 No.

PARTNER SEARCH FORM. MedAdvizor.org. Type of Company x HT R&D Research Institute University Other. Year Established 2013 No. 1. Company Profile 1.1 General Profile Full Name of Company MedAdvizor.org Registration # 514079573 Prior name of Company KDE Business Control Systems Ltd Type of Company x HT R&D Research Institute University

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

UNCLASSIFIED STATEMENT BY

UNCLASSIFIED STATEMENT BY UNCLASSIFIED FINAL STATEMENT BY CAROLYN J.M. BEST, PhD PROGRAM MANAGER OF THE PROSTATE CANCER RESEARCH PROGRAM OF THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS OF THE UNITED STATES ARMY MEDICAL

More information

Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer

Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages

More information

Loma Linda University and Siemens PETNET Solutions, Inc.

Loma Linda University and Siemens PETNET Solutions, Inc. Loma Linda University and Siemens PETNET Solutions, Inc. announce operational state-of-theart PET production and research facility to advance molecular imaging FOR IMMEDIATE RELEASE CONTACT: Susan Onuma

More information

MARIJUANA : A DRUG, MEDICINE, OR A DRUG AS MEDICINE? Robert Roose, MD, MPH, FASAM Sisters of Providence Health System Jan 15, 2016

MARIJUANA : A DRUG, MEDICINE, OR A DRUG AS MEDICINE? Robert Roose, MD, MPH, FASAM Sisters of Providence Health System Jan 15, 2016 MARIJUANA : A DRUG, MEDICINE, OR A DRUG AS MEDICINE? Robert Roose, MD, MPH, FASAM Sisters of Providence Health System Jan 15, 2016 EDUCATIONAL OBJECTIVES Describe the mechanism of action and effects of

More information

Fight against cancer US Need for New Approaches to Diagnosis and Therapy

Fight against cancer US Need for New Approaches to Diagnosis and Therapy Cancer Nanotechnology An Opportunity for Early Diagnosis and Novel Therapy: Developed vs Developing World Cost and Accessibility Piotr Grodzinski, Ph.D. Director, NCI Nanotechnology Alliance National Cancer

More information

Cancer Treatment Moringa Oleifera for Cancer Prevention or Treatment

Cancer Treatment Moringa Oleifera for Cancer Prevention or Treatment Cancer Treatment Moringa Oleifera for Cancer Prevention or Treatment As we learn more about cancer, we are empowered to use more of the tools which nature has created for us to help battle this terrible

More information

JUST THE FACTS: MARIJUANA AND MEDICINE

JUST THE FACTS: MARIJUANA AND MEDICINE Marijuana and Your Health: Just The Facts Part II JUST THE FACTS: MARIJUANA AND MEDICINE Is marijuana medicine? In short, smoked crude marijuana is not medicine. However, marijuana does have medicinal

More information

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety

More information

Technology funding opportunities at the National Cancer Institute

Technology funding opportunities at the National Cancer Institute Technology funding opportunities at the National Cancer Institute Through the Cancer Diagnosis Program http://cancerdiagnosis.nci.nih.gov/index.html Avraham Rasooly Ph.D. National Cancer Institute, Cancer

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root

More information

Master of Science in Vision Science and Investigative Ophthalmology MVSIO

Master of Science in Vision Science and Investigative Ophthalmology MVSIO Master of Science in Vision Science and Investigative Ophthalmology MVSIO Global Leadership in Eye Care, Vision Research and Ophthalmology Education Bascom Palmer Eye Institute is pleased to introduce

More information

National Cancer Institute

National Cancer Institute Technology Transfer Center National Cancer Institute NCI Shady Grove 9609 Medical Center Dr. Room 1E-530, MSC 9702 Bethesda, MD 20892-9702 Telephone: 240-276-5530 Fax: 240-276-5504 Technology Transfer

More information

Molecular Imaging and Prostate Cancer

Molecular Imaging and Prostate Cancer Molecular Imaging and Prostate Cancer Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. Based on rates from 2004 2006, the National Cancer Institute

More information

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs

More information

There are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine

There are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both

More information

A Guide to Medical Marijuana

A Guide to Medical Marijuana A Guide to Medical Marijuana Thousands of Marijuana Medicines Why Can Doctors Prescribe Only Two? By Sue Rusche President and CEO, National Families in Action April, 2014 National Families in Action has

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Annual Report on Form 20-F

Annual Report on Form 20-F Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines

More information

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including

More information

Homeopathy Efficacy of Ruta Graveolens in Brain Cancer & Leukemia

Homeopathy Efficacy of Ruta Graveolens in Brain Cancer & Leukemia Homeopathy Efficacy of Ruta Graveolens in Brain Cancer & Leukemia C.Health Tue, Sep-06-05, 06:27 This study from the International Journal of Oncology shows how the homeopathic remedy Ruta 6 used in conjunction

More information

Drug Discovery in China

Drug Discovery in China Drug Discovery in China Media Visit to Roche in China Shanghai 30 October 2005 Li Chen, Ph. D. Head of Research, Chief Scientific Officer Roche R&D Center (China) Ltd. Research Business Model in China

More information

INVITATION LETTER ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC.

INVITATION LETTER ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC. INVITATION LETTER COUNTRY: RWANDA SOURCE OF FUNDS: ORDINARY BUDGET ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC. REFERENCE NUMBER: 034/CS/ICS/2014-2015/RBC-MRC

More information

Increasing Patient Access through Oral Parity Legislation

Increasing Patient Access through Oral Parity Legislation Increasing Patient Access through Oral Parity Legislation The Leukemia & Lymphoma Society A powerhouse among nonprofits searching for cancer cures Our Mission; Cure leukemia, lymphoma, Hodgkin s disease

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Master of Bioethics Degree Program

Master of Bioethics Degree Program Master of Bioethics Degree Program Offered as a full-time (one-year) or part-time (two-year) course of study This degree program, offered by the Center for Bioethics at Harvard Medical School, offers education,

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

BS in Pharmaceutical Science (BSPS) degree program University of Rhode Island

BS in Pharmaceutical Science (BSPS) degree program University of Rhode Island To prepare students for careers in the pharmaceutical, biotechnical, consumer product and health care industries. Types of work include laboratory, regulatory oversight, engineering, economics, marketing,

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

Strategic Consulting Services

Strategic Consulting Services Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief

More information

www.iproteos.com Corporate Presentation November, 2013

www.iproteos.com Corporate Presentation November, 2013 www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)

More information

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,

More information

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. Treatments as unique as you are Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential

More information

What You Need to Know About Lung Cancer Immunotherapy

What You Need to Know About Lung Cancer Immunotherapy What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer

More information

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Not All Clinical Trials Are Created Equal Understanding the Different Phases Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact

More information

Malignant Mesothelioma - Pipeline Review, H2 2014

Malignant Mesothelioma - Pipeline Review, H2 2014 Brochure More information from http://www.researchandmarkets.com/reports/2888197/ Malignant Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Mesothelioma - Pipeline Review, H2 2014 Summary

More information

Fulfilling the Promise

Fulfilling the Promise Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

Company Profile // May 2012

Company Profile // May 2012 Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for

More information

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter)

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

209: Using Competitive Intelligence to Drive your IP Portfolio

209: Using Competitive Intelligence to Drive your IP Portfolio ACC s 2013 Annual Meeting Monday, October 28 11:00 AM - 12:30 PM 209: Using Competitive Intelligence to Drive your IP Portfolio Christine Collard Partner Borden Ladner Gervais LLP Ywe Looper Director,

More information

Bioethics Education in Professional Science Master s Programs at California State University Channel Islands

Bioethics Education in Professional Science Master s Programs at California State University Channel Islands ETHICS AND THE PSM Bioethics Education in Professional Science Master s Programs at California State University Channel Islands Ching-Hua Wang, M.D., Ph.D., Director of MS Biotechnology and Bioinformatics

More information

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

More information

TREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE

TREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE Providing the best in cancer care for Veterans TREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE VA Pittsburgh s state-of-the-art TomoTherapy machine, which delivers radiation to patients.

More information

HISTORY OF ESCOZINE FOR PETS

HISTORY OF ESCOZINE FOR PETS HISTORY OF ESCOZINE FOR PETS Table of Contents I. Escozine For Pets verses Escozul / Vidatox... 2 II. Patent... 2 III. Labiofam... 2 IV. Location / Natural Habitat of the Caribbean Blue Scorpion... 3 V.

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Contents. Page 1 of 21

Contents. Page 1 of 21 Programme-specific Section of the Curriculum for the MSc Programme in Biochemistry at the Faculty of Science, University of Copenhagen 2009 (Rev. 2015) Contents... 1 1 Title, affiliation and language...

More information

Aposense Enhancing Drug Effects

Aposense Enhancing Drug Effects Aposense Enhancing Drug Effects Miri Ben-Ami, M.D. CEO IATI Biomed June 2013 Aposense Proprietary FORWARD LOOKING STATEMENTS The following slides contain forward-looking statements that include, but are

More information

TERM SHEET EXAMPLE. 1 P age

TERM SHEET EXAMPLE. 1 P age 1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

Overview of the Specialty Drug Trend

Overview of the Specialty Drug Trend WHITE PAPER Overview of the Specialty Drug Trend Succeeding In The Rapidly Changing U.S. Specialty Market 1 Specialty drugs are prescribed to treat complex conditions such as cancer, HIV and inflammatory

More information

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL INTRODUCTION BY INNOVATION CENTRE DENMARK IN SAO PAULO BRAZILIAN BIOTECHNOLOGY SECTOR The Ministry of Science, Technology and Innovation (MCTI) considers

More information

A Career in Pediatric Hematology-Oncology? Think About It...

A Career in Pediatric Hematology-Oncology? Think About It... A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

More information